![Peter Dritschilo](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Dritschilo
President bij SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Vermogen: 3 483 $ op 31-05-2024
Actieve functies van Peter Dritschilo
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | President | 18-12-2012 | - |
Operationeel Directeur | 18-12-2012 | - | |
Directeur/Bestuurslid | 18-12-2012 | - | |
Shuttle Pharmaceuticals, Inc.
![]() Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Operationeel Directeur | 01-12-2012 | - |
President | 01-12-2012 | - |
Loopbaan van Peter Dritschilo
Opleiding van Peter Dritschilo
Georgetown University | Undergraduate Degree |
The GW School of Business | Masters Business Admin |
Statistieken
Internationaal
Verenigde Staten | 5 |
Operationeel
Chief Operating Officer | 2 |
President | 2 |
Undergraduate Degree | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Shuttle Pharmaceuticals, Inc.
![]() Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
- Beurs
- Insiders
- Peter Dritschilo
- Ervaring